Diamond Hill Capital Management Inc. Has $21.64 Million Stock Position in Humana Inc. (NYSE:HUM)

Diamond Hill Capital Management Inc. trimmed its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 89.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,294 shares of the insurance provider's stock after selling 708,204 shares during the period. Diamond Hill Capital Management Inc. owned about 0.07% of Humana worth $21,640,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in Humana during the fourth quarter valued at about $27,000. Centricity Wealth Management LLC bought a new position in Humana during the fourth quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new position in Humana during the third quarter valued at about $31,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Finally, OFI Invest Asset Management acquired a new stake in shares of Humana in the fourth quarter valued at about $33,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is currently owned by corporate insiders.

Remove Ads

Humana Price Performance

NYSE HUM traded up $5.45 during trading on Tuesday, reaching $269.86. 1,632,536 shares of the company traded hands, compared to its average volume of 1,713,453. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock's 50 day moving average price is $271.39 and its two-hundred day moving average price is $278.89. The company has a market cap of $32.57 billion, a price-to-earnings ratio of 27.12, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana's dividend payout ratio (DPR) is currently 35.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HUM shares. JPMorgan Chase & Co. lowered their price target on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. StockNews.com downgraded Humana from a "buy" rating to a "hold" rating in a research report on Tuesday. Barclays raised their price target on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.